Safety and immunogenicity evaluation of recombinant E.coli BK-SE36 malaria vaccine candidate with aluminium hydroxide gel as adjuvant administered either subcutaneously or intramuscularly in healthy malaria exposed African children living in Burkina Faso: A double blinded, randomized, controlled, age de-escalating, phase Ib clinical trial.

Trial Profile

Safety and immunogenicity evaluation of recombinant E.coli BK-SE36 malaria vaccine candidate with aluminium hydroxide gel as adjuvant administered either subcutaneously or intramuscularly in healthy malaria exposed African children living in Burkina Faso: A double blinded, randomized, controlled, age de-escalating, phase Ib clinical trial.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Malaria vaccine (Primary) ; Malaria vaccine (Primary) ; Aluminium hydroxide; Aluminium hydroxide
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Sponsors Nobelpharma
  • Most Recent Events

    • 04 Apr 2017 Status changed from active, no longer recruiting to discontinued.
    • 16 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top